Gelesis Holdings Inc (GLS) Gross Profit Margin starting from the second quarter 2023 to second quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Gelesis Holdings Inc   (GLS)


Gelesis Holdings Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLS Gross Profit Margin (Jun 30 2023)
Q2 		(Mar 31 2023)
Q1 		(Dec 31 2022)
Q4 		(Sep 30 2022)
Q3 		(Jun 30 2022)
Q2
Y / Y Revenue Change -87.66 %
Seq. Revenue Change -36.85 %
Revenue In Millions $1.11
Gross Profit Margin 55.01 %
Gross Profit Margin Total Ranking # 1689
Gross Profit In Millions $0.61
Y / Y Gross Profit Change -85.45 %
Seq. Gross Profit Change 18.02 %


Commenting Second Quarter 2023 Gross Profit Margin
Gelesis Holdings Inc achieved Gross Profit of $1 millions compare to Gross Loss of $0.52 millions booked in the previous quarter. Despite the sequential Revenue deterioration in Q2 of -36.85 % Gelesis Holdings Inc managed to reduce Cost of Sales and increase Gross Profit by 18.02 % to $1 millions. Gross Profit Margin grew to 55.01 % a new company high.


Observing second quarter 2023 results within Major Pharmaceutical Preparations industry 121 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1689, from total ranking in the previous quarter at 2820.
Learn about Gross Margin
GLS's Gross Profit Margin second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 122
Healthcare Sector # 310
Overall # 1666

Gross Profit Margin Statistics
High Average Low
55.01 % 42.27 % 29.44 %
(Jun 30 2023)   (Mar 31 2023)


GLS Gross Income Trends • More of GLS's Profitabilty Ratios • GLS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
GLS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
GLS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for GLS's Competitors
Gross Profit Margin Profit Margin for Gelesis Holdings Inc 's Suppliers
Gross Profit Margin Profit Margin for GLS's Customers

You may also want to know
GLS's Annual Growth Rates GLS's Profitability Ratios GLS's Asset Turnover Ratio GLS's Dividend Growth
GLS's Roe GLS's Valuation Ratios GLS's Financial Strength Ratios GLS's Gross Profit Growth
GLS's Roa GLS's Inventory Turnover Ratio GLS's Growth Rates GLS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2023 MRQ Gross ProfitJun 30 2023 MRQ Revenue
Ptc Therapeutics inc   99.86 %$ 213.508  Millions$ 213.808  Millions
Intercept Pharmaceuticals inc   99.78 %$ 83.533  Millions$ 83.718  Millions
Deciphera Pharmaceuticals Inc   99.55 %$ 38.131  Millions$ 38.304  Millions
Corcept Therapeutics Inc  98.66 %$ 116.141  Millions$ 117.715  Millions
Macrogenics Inc   98.04 %$ 12.878  Millions$ 13.136  Millions
Avadel Pharmaceuticals Plc  97.59 %$ 1.460  Millions$ 1.496  Millions
2seventy Bio Inc   97.48 %$ 35.141  Millions$ 36.048  Millions
Lexicon Pharmaceuticals Inc   97.48 %$ 0.309  Millions$ 0.317  Millions
Trevena inc   97.09 %$ 2.933  Millions$ 3.021  Millions
Karyopharm Therapeutics Inc   96.82 %$ 36.385  Millions$ 37.579  Millions
Travere Therapeutics Inc   96.67 %$ 57.707  Millions$ 59.697  Millions
Gyre Therapeutics Inc   96.33 %$ 28.252  Millions$ 29.329  Millions
Aurinia Pharmaceuticals Inc   96.23 %$ 39.931  Millions$ 41.494  Millions
Rigel Pharmaceuticals Inc  96.00 %$ 25.811  Millions$ 26.886  Millions
Blueprint Medicines Corporation  95.96 %$ 55.247  Millions$ 57.570  Millions
Acadia Pharmaceuticals Inc   95.49 %$ 157.776  Millions$ 165.235  Millions
Emmaus Life Sciences Inc   95.28 %$ 10.251  Millions$ 10.759  Millions
Amylyx Pharmaceuticals Inc   94.32 %$ 92.636  Millions$ 98.216  Millions
Bioxcel Therapeutics Inc   94.31 %$ 0.431  Millions$ 0.457  Millions
Palatin Technologies Inc   94.10 %$ 1.658  Millions$ 1.762  Millions
Regeneron Pharmaceuticals Inc   93.91 %$ 2,965.700  Millions$ 3,158.100  Millions
Marinus Pharmaceuticals Inc   93.65 %$ 5.695  Millions$ 6.081  Millions
Celularity Inc   92.95 %$ 2.731  Millions$ 2.938  Millions
Vanda Pharmaceuticals Inc   92.40 %$ 42.557  Millions$ 46.056  Millions
Zevra Therapeutics Inc   92.01 %$ 7.793  Millions$ 8.470  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions
Sage Therapeutics Inc   91.71 %$ 2.269  Millions$ 2.474  Millions
Ocular Therapeutix Inc   91.41 %$ 13.882  Millions$ 15.186  Millions
Ultragenyx Pharmaceutical Inc   90.85 %$ 98.395  Millions$ 108.309  Millions
Amicus Therapeutics inc   90.46 %$ 85.389  Millions$ 94.389  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.